Long Covid Newsletter
Issue #31April 6, 20267 studies

Fluvoxamine reduces long COVID fatigue in 399 patients by 60 days

New research this week brings the first promising drug treatment for long COVID fatigue, reveals striking funding gaps for conditions affecting women, and uncovers surprising heart changes in kids with post-COVID syndrome.

🧬 First Drug Shows Promise Against Long COVID Fatigue

  • Fluvoxamine (an antidepressant) significantly reduced fatigue in 399 long COVID patients compared to placebo after 60 days of treatment

  • The drug showed sustained benefits even 30 days after stopping treatment, with patients reporting better quality of life

  • Side effects were actually lower with fluvoxamine (20%) than with placebo (29.7%), while metformin showed no benefit despite being tested alongside

Why it matters: This is the first randomized controlled trial to show a medication can meaningfully improve long COVID fatigue, potentially offering hope to millions struggling with this debilitating symptom.

🥈 Top 2% journal 🔗 Annals of internal medicine Journal Article 🗓️ Mar 30

Key Findings

💰 Long COVID Gets 14% of Funding It Deserves Based on Disability Burden

  • Long COVID received only $106 million in NIH funding versus the $739.8 million it would get if funding matched its disability burden

  • Female-predominant conditions receive 5.2 times less funding per disability unit than male-predominant conditions ($1.3 million vs $7.0 million per unit)

  • Among the 12 most underfunded conditions relative to their impact, 7 disproportionately affect women while none primarily affect men

💡 Systematic underfunding of conditions affecting women may help explain why treatments for long COVID and similar syndromes remain elusive.
🥉 Top 5% journal 🔗 Communications medicine Journal Article 🗓️ Mar 31

❤️ Kids with Long COVID Show Hidden Heart Changes

  • 100 children with post-COVID syndrome had significantly reduced right heart muscle function compared to 20 healthy controls, despite normal standard heart tests

  • Advanced cardiac MRI revealed decreased right ventricle strain (22.6% vs 27.1%) and slightly increased heart muscle mass

  • Left heart function remained completely normal, suggesting the right side of the heart bears the brunt of long COVID effects in children

💡 Subtle heart changes in kids with long COVID may help explain exercise limitations, even when routine heart tests appear normal.
Top 20% journal 🔗 Frontiers in cardiovascular medicine Journal Article 🗓️ Apr 2

🔬 Single Patient Recovers from Severe Long COVID with Immune Treatment

  • A 39-year-old man with disabling long COVID showed complete recovery after high-dose intravenous immunoglobulin therapy over one year

  • Treatment reduced harmful immune cell interactions and autoantibodies that may drive long COVID symptoms

  • Fatigue scores normalized and cognitive function returned to normal, though this represents just one case and can't establish causation

💡 This case suggests immune system dysfunction may drive severe long COVID and that targeted treatments could help selected patients.
🥇 Top 1% journal 🔗 The Lancet. Infectious diseases Review 🗓️ Apr 3

📊 Women Face Higher Long COVID Risk, But Social Class Matters

  • Analysis of 535,300 Americans found higher socioeconomic status doesn't equally protect all groups from long COVID

  • High-income Black women showed significantly elevated long COVID rates compared to high-income White women

  • Among high-income White women, the typical female advantage in long COVID risk nearly disappeared, suggesting social privilege can mitigate health risks

💡 Structural inequalities, rather than biology alone, may drive long COVID disparities across race and gender lines.
Top 20% journal 🔗 Sociology of health & illness Journal Article 🗓️ Mar 31

🧪 Long COVID and HIV Share Some Immune Problems, Differ in Others

  • Study of 557 people found long COVID patients had elevated oxidized cholesterol markers compared to both HIV patients and healthy controls

  • HIV patients showed worse vitamin K status, which was strongly linked to inflammation across all groups

  • Both conditions involve chronic immune dysfunction but through distinct inflammatory pathways

💡 Understanding shared immune pathways between long COVID and HIV could guide development of treatments for both conditions.
🥉 Top 5% journal 🔗 The Journal of infectious diseases Journal Article 🗓️ Mar 31

🎯 Cancer Patients Dodged Long COVID During Omicron Wave

  • 39,256 cancer patients infected during Omicron showed no increased risk of long COVID compared to 37,551 uninfected cancer patients

  • However, cancer patients hospitalized for COVID-19 still faced 36% higher risk of new diagnoses and 48% higher risk of persistent symptoms

  • 93% of patients were boosted, suggesting vaccination protected this vulnerable population from long COVID during the milder Omicron era

💡 High vaccination rates may have successfully protected cancer patients from long COVID during the Omicron variant's dominance.
🥈 Top 2% journal 🔗 JAMA network open Journal Article 🗓️ Mar 31

Implications

This week's research suggests long COVID may finally have its first effective treatment, but also reveals how funding inequities and social disparities shape who gets help. The emerging picture shows long COVID as a complex condition requiring both medical innovation and systemic change to address fairly.

Studies in this issue

Primary sources used for this newsletter.

  1. Fluvoxamine and Metformin may reduce fatigue in long COVID patients: A flexible clinical trial
    main storyAnnals of internal medicine2026-03-30PMID 41911553
  2. Long-term aftereffects of Omicron COVID-19 in cancer patients
    key findingJAMA network open2026-03-31PMID 41915390
  3. Heart and blood vessel characteristics in children and teens at first diagnosis of long COVID
    key findingFrontiers in cardiovascular medicine2026-04-02PMID 41924624
  4. Immune Activation and Gut Barrier Problems in Long COVID Compared to HIV Infection
    key findingThe Journal of infectious diseases2026-03-31PMID 41914490
  5. How overlapping social inequalities affect long COVID risk in the United States
    key findingSociology of health & illness2026-03-31PMID 41914537
  6. Disability from Long COVID in US Adults
    key findingCommunications medicine2026-03-31PMID 41917225
  7. Intravenous antibody treatment for long COVID: a report of patient symptoms and immune responses
    key findingThe Lancet. Infectious diseases2026-04-03PMID 41932347

Continue reading

All Long Covid issues